Nesiritide: Trials and tribulations

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 3, 2006, Pages 165-169

  Arora, Rohit R ^a,b,c  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b SCIOS INC   (United States)

^c NCVA   (United States)

Author keywords

Decompensated heart failure; Nesiritide; Renal function

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; DIURETIC AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; VASODILATOR AGENT;

ACUTE HEART FAILURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG INDICATION; HEMODYNAMICS; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

ACUTE DISEASE; CREATININE; DECISION MAKING; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE; META-ANALYSIS; META-ANALYSIS AS TOPIC; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 33749558157     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406291155     Document Type: Review

References (28)

1. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
2. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
3. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2005;13:1-199.
4. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649-660.
5. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
6. Emerman CE, DeMarco T, Costanzo MR, Peacock WF. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry [abstract 368]. J Card Fail. 2004;10(suppl 4):S116.
7. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial [abstract 2415]. Circulation. 2004;110(suppl 3):III-515.
8. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
9. Peacock WF, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: Results from the proaction trial. J Emerg Med. 2005;29:243-252.
10. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 1999;34:155-162.
11. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
12. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT Study. Am Heart J. 2002;144:1102-1108.
13. Burger AJ: Risk of death with nesiritide. JAMA. 2005;294:897.
14. Gortney JS, Porter KB. Risk of death with nesiritide. JAMA. 2005;294:897-898.
15. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
16. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure. Am J Cardiol. 2000;85:1110-1113.
17. Smith GE, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13-25.
18. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract #2789]. Circulation. 2005;589.
19. Burger A. Clinical predictors of worsening renal function in patients hospitalized for heart failure [abstract #2791]. Circulation. 2005;2791.
20. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine [abstract 240], 2005. Available at: Heart Failure Society of America Website, http://www.hfsa.org/. Accessed June 16, 2006.
21. Heywood JT. Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstract 255], 2005. Available at: Heart Failure Society of America Website, http://www.hfsa.org/. Accessed June 16, 2006.
22. Elkayam U. Nesiritide may diminish the increased acute mortality risk associated with worsening renal function [abstract #3168]. Circulation. 2005;676.
23. Abraham WT. Effect of baseline covariates on mortality risk in the vasodilation in the management of acute congestive heart failure (VMAC) trial [abstract #2790]. Circulation. 2005;589.
24. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk [abstract #3169]. Circulation. 2005;676.
25. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
26. Abbott Laboratories. Abbott reports improved clinical course with levosimendan (Simdax) when added to standard therapy in acute decompensated heart failure trial [press release]. 2005. Available at http://www.abbott.com/. Accessed, June 16, 2006.
27. Abbott Laboratories. Abbott reports levosimendan (Simdax) results from large mortality trial in patients with acute decompensated heart failure [press release]. 2005. Available at http://www.abbott.com. Accessed June 16, 2006.
28. Hebeler RF Jr, Oz MC. Effect of Perioperative Nesiritide Administration on Post Operative Renal Function and Clinical Outcomes in Patients Undergoing Cardiothoracic Surgery. 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; May 9, 2006, Washington, DC. Poster 104, Abstract 292.